Literature DB >> 25601037

Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.

Seamus O'Brien1.   

Abstract

The rise of antibiotic resistance is leading to clinicians being increasingly faced with clinical failure due to the lack of effective and safe treatment options. New antibiotics are needed now for current multi-drug resistant infections but also in preparation for emerging and anticipated threats. There are significant challenges for the pharmaceutical industry to discover and develop new antibiotics including a business model that balances reasonable reimbursement with appropriate use. This summary reviews the key challenges and collaborative interventions that may contribute to addressing a societal problem.
© 2014 The British Pharmacological Society.

Mesh:

Substances:

Year:  2015        PMID: 25601037      PMCID: PMC4309623          DOI: 10.1111/bcp.12401

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.

Authors:  Brad Spellberg; Priya Sharma; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

3.  Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013.

Authors:  C Glasner; B Albiger; G Buist; A Tambić Andrasević; R Canton; Y Carmeli; A W Friedrich; C G Giske; Y Glupczynski; M Gniadkowski; D M Livermore; P Nordmann; L Poirel; G M Rossolini; H Seifert; A Vatopoulos; T Walsh; N Woodford; T Donker; D L Monnet; H Grundmann
Journal:  Euro Surveill       Date:  2013-07-11

4.  A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.

Authors:  John H Rex; Barry I Eisenstein; Jeff Alder; Mark Goldberger; Robert Meyer; Aaron Dane; Ian Friedland; Charles Knirsch; Wendy R Sanhai; John Tomayko; Cindy Lancaster; Jennifer Jackson
Journal:  Lancet Infect Dis       Date:  2013-01-15       Impact factor: 25.071

5.  Is the GAIN Act a turning point in new antibiotic discovery?

Authors:  Eric D Brown
Journal:  Can J Microbiol       Date:  2013-02-06       Impact factor: 2.419

Review 6.  Platforms for antibiotic discovery.

Authors:  Kim Lewis
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

7.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Authors:  Paul G Ambrose; Sujata M Bhavnani; Christopher M Rubino; Arnold Louie; Tawanda Gumbo; Alan Forrest; George L Drusano
Journal:  Clin Infect Dis       Date:  2006-11-27       Impact factor: 9.079

Review 8.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 9.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

10.  Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study.

Authors:  Mikhail V Edelstein; Elena N Skleenova; Oksana V Shevchenko; Jimson W D'souza; Dmitry V Tapalski; Ilya S Azizov; Marina V Sukhorukova; Roman A Pavlukov; Roman S Kozlov; Mark A Toleman; Timothy R Walsh
Journal:  Lancet Infect Dis       Date:  2013-07-09       Impact factor: 25.071

View more
  6 in total

Review 1.  Cooperative development of antimicrobials: looking back to look ahead.

Authors:  Carl Nathan
Journal:  Nat Rev Microbiol       Date:  2015-10       Impact factor: 60.633

2.  From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.

Authors:  Jennifer H Martin; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  Evaluating the Potential and Synergetic Effects of Microcins against Multidrug-Resistant Enterobacteriaceae.

Authors:  Soufiane Telhig; Laila Ben Said; Carmen Torres; Sylvie Rebuffat; Séverine Zirah; Ismail Fliss
Journal:  Microbiol Spectr       Date:  2022-05-11

4.  Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase.

Authors:  Pan F Chan; Thomas Germe; Benjamin D Bax; Jianzhong Huang; Reema K Thalji; Eric Bacqué; Anna Checchia; Dongzhao Chen; Haifeng Cui; Xiao Ding; Karen Ingraham; Lynn McCloskey; Kaushik Raha; Velupillai Srikannathasan; Anthony Maxwell; Robert A Stavenger
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

Review 5.  The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents.

Authors:  Frederic Collin; Anthony Maxwell
Journal:  J Mol Biol       Date:  2019-06-08       Impact factor: 5.469

Review 6.  Benzofuran as a promising scaffold for the synthesis of antimicrobial and antibreast cancer agents: A review.

Authors:  Ghadamali Khodarahmi; Parvin Asadi; Farshid Hassanzadeh; Elham Khodarahmi
Journal:  J Res Med Sci       Date:  2015-11       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.